Patents Examined by Carla J. Myers
  • Methods for subtyping of lung squamous cell carcinoma
    Patent number: 11041214
    Abstract: Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: June 22, 2021
    Assignees: GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Hawazin Faruki, Myla Lai-Goldman, Greg Mayhew, Jonathan Serody, Charles Perou, David Neil Hayes
  • Method for predicting a subject's response to valproic acid therapy
    Patent number: 11041207
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 22, 2021
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
    Inventors: Catherine L. Clelland, James D. Clelland
  • IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors
    Patent number: 11035007
    Abstract: The present disclosure provides systems and methods for the highly sensitive and effective treatment and diagnosis of cancer. The methods disclosed herein take advantage of the discovery of a series of newly identified, inter-chromosomal genetic fusion events that occur upstream from the IGF2BP3 gene, which result in elevated expression of IGF2BP3 protein. The present disclosure utilizes biomarkers developed using this set of newly discovered genetic fusion events and elevated expression of IGF2BP3 protein to not only diagnosis cancer with high sensitivity and reliability, but also to pre-select patient populations that are expected to display an elevated likelihood of success when treated with any of numerous inhibitors of IGF1R-mediated signaling.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 15, 2021
    Assignees: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Yuri E Nikiforov, Marina N Nikiforova
  • Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension
    Patent number: 11028448
    Abstract: The disclosure relates to methods of identifying subjects at risk of developing bevacizumab-induced toxicities such as proteinuria and/or hypertension involving measuring nucleic acid or gene mutations in a sample obtained from the subject.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 8, 2021
    Assignees: The University of North Carolina at Chapel Hill, Duke University
    Inventors: Federico Innocenti, Julia Quintanilha, Danyu Lin, Kouros Owzar, Jin Wang
  • Assay for the diagnosis of dermatophytosis
    Patent number: 11028452
    Abstract: The present invention relates to a primer pair comprising a forward primer and a reverse primer for amplifying a nucleic acid from a pathogen associated with a skin, hair and nail infection comprising SEQ ID NO:22, a nucleic acid capable of hybridizing specifically to a nucleic acid sequence from a pathogen associated with a skin, hair and nail infection comprising SEQ ID NO:22, a carrier comprising the nucleic acid, a method comprising the step detecting in a sample a nucleic acid sequence comprising SEQ ID NO:22 from a pathogen associated with a skin, hair and nail infection, a use of the primer pair, the nucleic acid or the carrier for the diagnosis of a disease and a kit comprising the primer pair, the nucleic acid and/or the carrier for the diagnosis of a disease.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 8, 2021
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Melanie Harder, Yvonne Graeser, Christiane Kupsch, Markus Cavalar
  • Method for evaluating the risk of drug hypersensitivity reaction induced by Sulfamethoxazole and Trimethoprim
    Patent number: 11028437
    Abstract: Provided is a method for evaluating the risk of drug hypersensitivity reaction induced by antibiotics sulfamethoxazole and/or trimethoprim. The drug hypersensitivity reaction comprises: maculopapular eruption, fixed drug eruption, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms. A specific HLA genotype is associated with the drug hypersensitivity reaction induced by the antibiotics sulfamethoxazole and/or trimethoprim.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: June 8, 2021
    Assignee: Chang Gung Memorial Hospital, Linkou
    Inventors: Wen-Hung Chung, Shuen-Iu Hung
  • Methods for predicting prostate cancer relapse
    Patent number: 11008624
    Abstract: The present invention relates to methods for determining whether a subject having prostate cancer is at an increased risk for relapse or rapid relapse. It is based, at least in part, on the results of a comprehensive genome analysis of 273 prostate cancer samples, which indicate that the percentage of large size CNVs predicts prostate cancer relapse. In certain embodiments, a method for determining whether a prostate cancer patient has an increased risk of suffering a relapse or a rapid relapse comprises determining the number and size of CNVs in a sample and determining a large size ratio, where if the large size ratio exceeds a particular threshold, the patient is deemed to be at an increased risk for relapse or rapid relapse.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: May 18, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yanping Yu, Chien-Cheng Tseng, Shuchang Liu, George Michalopoulos, Joel Nelson
  • Methods for treating cancer resistant to ErbB therapeutics
    Patent number: 11008620
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 18, 2021
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Methods for diagnosing, prognosing, and treating parkinsonism
    Patent number: 11008614
    Abstract: This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: May 18, 2021
    Assignee: Population Bio, Inc.
    Inventors: Eli Hatchwell, Peggy S. Eis
  • Detective molecule, kit and method for predicting fragrance production in an orchid
    Patent number: 10988815
    Abstract: The invention relates to a detective molecule, and more particularly to a detective molecule and a kit for detecting a target molecule, a method for predicting fragrance production in an orchid, and a method for breeding a scented orchid.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: April 27, 2021
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Hong-Hwa Chen, Yu-Chen Chuang, Wen-Chieh Tsai, Yi-Chu Hung, Wen-Huei Chen, Chi-Yu Hsu, Chuan-Ming Yeh, Nobutaka Mitsuda, Masaru Ohme-Takagi
  • Methods of detecting prenatal or pregnancy-related diseases or conditions
    Patent number: 10961578
    Abstract: This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of prenatal or pregnancy-related diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of prenatal or pregnancy-related diseases or conditions.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 30, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventor: Amin I. Kassis
  • Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
    Patent number: 10961583
    Abstract: The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: March 30, 2021
    Assignee: Regeneron Phramaceuticals, Inc.
    Inventors: Yurong Xin, Jesper Gromada, Xiping Cheng, Frederick Dewey, Tanya Teslovich Dostal, Claudia Schurmann, Aris Baras, Noura Abul-Husn
  • Method for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment
    Patent number: 10954563
    Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 23, 2021
    Assignees: UNIVERSITAT DE BARCELONA, HOSPITAL CLINIC DE BARCELONA, INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUSUST PI 1 -SUNYER, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER)
    Inventors: Sergi Mas Herrero, Patricia Gassó Astorga, Cristina Malagelada Grau, Miquel Bernardo Arroyo, Amalia Lafuente Flo
  • Compositions and method for treating complement-associated conditions
    Patent number: 10947591
    Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: March 16, 2021
    Assignee: Genentech, Inc.
    Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
  • Methods for subtyping of lung adenocarcinoma
    Patent number: 10934595
    Abstract: Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 2, 2021
    Assignees: GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Hawazin Faruki, Myla Lai-Goldman, Greg Mayhew, Jonathan Serody, Charles Perou, David Neil Hayes
  • Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
    Patent number: 10927413
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: February 23, 2021
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNTVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSIT MAINZ GGMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • Determination of miR-423-5p in heart failure
    Patent number: 10913979
    Abstract: The present invention relates to methods, kits and uses for diagnosing heart failure using miRNA-biomarker from blood.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: February 9, 2021
    Assignee: HUMMINGBIRD DIAGNOSTICS GMBH
    Inventors: Markus Beier, Thomas Brefort
  • Methods for predicting drug responsiveness in cancer patients
    Patent number: 10907214
    Abstract: The present invention features methods, devices, and kits for detecting a level of one or more biomarkers in a patient having cancer or determining the responsiveness of a patient having cancer to a treatment, such as treatment with a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome. The invention further includes methods of treating a patient having cancer by administering, e.g., the liposome.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 2, 2021
    Assignee: Oncology Venture ApS
    Inventor: Steen Knudsen
  • Systems and methods for obtaining biological molecules from a sample
    Patent number: 10889861
    Abstract: The present invention relates to a method of creating a biomarker profile, the method comprising the steps of: obtaining a sample of biofluid from a subject, wherein the sample is stored on a sample collection apparatus; removing the sample from the sample collection apparatus; extracting nucleic acids from the sample; sequencing the extracted nucleic acids to generate sequence data; and analyzing the sequence data using a two-step analytical methodology to create the biomarker profile. The present invention athletic performance in a subject.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 12, 2021
    Assignee: The Translational Genomics Research Institute
    Inventor: Matthew Huentelman
  • Splice variants associated with neomorphic SF3B1 mutants
    Patent number: 10889866
    Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: January 12, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes